1. Friedman, H.M., and Glaubiger, D.L. (1982) Assessment of in vitro drug sensitivity of human tumor cells using thymidine incorporation in a modified human tumor stem cell. Cancer Res. 42, 4683–4689.
2. Naito, K., Skog, S., Tribukait. B., Andersson. L., Hisazumi. H. (1987) Cell cycle related [3H]-thymidine uptake and its significance for the incorporation into DNA. Cell Tissue Kinet.
20, 447–457.
3. Harrington, E.A., Bebbington, D., Moore, J., Rasmussen, R.K., Ajose-Abeogun, A., Nakayama, T., Graham, J.A., Demur, C., Hercend, T., Diu-Hercend, A., Su, M., Golec, J.M., Miller, K.M. (2004). VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases suppresses tumour growth in vivo. Nature Med. 10, 262–267.
4. Hennequin, L.F., Thomas, A.P., Johnstone, C., Stokes, E.S.E., Ple, P.A., Lohmann, J.M., Ogilve, D.J., Dukes, M., Wedge, S.R., Curwen, J.O., Kendrew, J., Lambert-van der Bempt, C. (1999). Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 42, 5369–5389.
5. Ogita, H., Isobe, Y., Takaku, H., Sekine, R., Goto, Y., Misawa, S., Hayashi, H. (2001). Synthesis and structure-activity relationship of diarylamide derivatives as selective inhibitors of the proliferation of human coronary artery smooth muscle cells. Bioorganic & Med. Chem. Lett.
11, 549–551.